Compare FMBH & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | AVLN |
|---|---|---|
| Founded | 1865 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1995 | 2026 |
| Metric | FMBH | AVLN |
|---|---|---|
| Price | $50.68 | $35.33 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | 93.3K | ★ 168.0K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 16.06 | N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | $24.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.51 | $24.90 |
| 52 Week High | $53.36 | $40.17 |
| Indicator | FMBH | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 55.36 |
| Support Level | $50.49 | $34.22 |
| Resistance Level | $53.36 | $40.08 |
| Average True Range (ATR) | 0.91 | 1.91 |
| MACD | -0.10 | -0.46 |
| Stochastic Oscillator | 74.84 | 35.63 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.